Table 3.
Recurrence and survival among patients in the RATE and TE groups.
| Robot (N = 51) | Thoracoscopy (N = 70) | P | |
|---|---|---|---|
| Recurrence | 0.393 | ||
| None | 40 (78%) | 51 (73%) | |
| Recurred | 11 (22%) | 19 (27%) | |
| Lymph node recurrence within the surgical field | 0.137 | ||
| None | 51 (100%) | 66 (94%) | |
| Recurred within the surgical field | 0 (0%) | 4 (6%) | |
| Overall local recurrence (including anastomotic site) | 0.039* | ||
| None | 51 (100%) | 64 (91%) | |
| Recurred within a local field | 0 (0%) | 6 (9%) | |
| Recurrence pattern | 0.189 | ||
| None | 40 (78%) | 51 (73%) | |
| Local field | 0 (0%) | 6 (9%) | |
| Distant lymph node | 4 (8%) | 5 (7%) | |
| Distant organs | 7 (14%) | 8 (11%) | |
| Survival | 0.947 | ||
| Alive | 40 (78%) | 55 (79%) | |
| Esophageal cancer-specific death | 8 (16%) | 10 (14%) | |
| Death from other diseases | 3 (6%) | 5 (7%) | |
| Disease-free survival rate | 0.697# | ||
| 1-year survival rate | 76.5% | 81.4% | |
| 2-year survival rate | 74.1% | 71.8% | |
| 3-year survival rate | 74.1% | 64.7% | |
*Statistically significant difference.
#Log-rank test.